vosoritide

FDA Drug Profile — VOXZOGO 1.2mg, VOXZOGO 0.56mg, VOXZOGO 0.4mg

Drug Details

Generic Name
vosoritide
Brand Names
VOXZOGO 1.2mg, VOXZOGO 0.56mg, VOXZOGO 0.4mg
Application Number
NDA214938
Sponsor
BioMarin Pharmaceutical Inc.
NDC Codes
3
Dosage Forms
KIT
Routes
N/A
Active Ingredients
N/A

Indications and Usage

1 INDICATIONS AND USAGE VOXZOGO is indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). VOXZOGO is a C type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1 )